Article
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Kidney & blood pressure research - 1 Jan 2018
Sperl Jan, Kreidlova Miluse, Merta Dusan, Chmelova Klara, Senkerikova Renata, Frankova Sona
Abstract excerpt
BACKGROUND/AIMS: Chronic hepatitis C (HCV) virus infection reactivates under immunosuppressive drugs and therefore has a negative impact on long-term survival of kidney transplant recipients. Treatment-induced clearance of hepatitis C virus (HCV) in kidney transplant candidates prevents virus reactivation after transplantation. Paritaprevir/Ritonavir/Ombitasvir with Dasabuvir (PrOD) represents a highly effective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.